N‐Acetyl‐L‐Cysteine (NAC) Blunts Axitinib‐Related Adverse Effects in Preclinical Models of Glioblastoma

N‐Acetyl‐L‐Cysteine (NAC) Blunts Axitinib‐Related Adverse Effects in Preclinical Models of Glioblastoma

ABSTRACT Objective Axitinib is a tyrosine kinase inhibitor characterized by a strong affinity for Vascular Endothelial Growth Factor Receptors (VEGFRs). It was approved in 2012 by Food and Drug Administration and European Medicines Agency as a second line treatment for advanced renal cell carcinoma...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessia Formato, Maria Salbini, Elisa Orecchini, Manuela Pellegrini, Mariachiara Buccarelli, Lucia Ricci Vitiani, Stefano Giannetti, Roberto Pallini, Quintino Giorgio D'Alessandris, Liverana Lauretti, Maurizio Martini, Valentina De Falco, Andrea Levi, Maria Laura Falchetti, Maria Patrizia Mongiardi
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Cancer Medicine
Subjects:
axitinib
brain tumor xenograft
endothelium
glioblastoma IDH‐wild type
glioma stem cells
N‐acetyl‐L‐cysteine
Online Access:https://doi.org/10.1002/cam4.70279
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70279

Similar Items